Mavik Patent Expiration

Mavik is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2015. Details of Mavik's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5744496 Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
Apr, 2015

(9 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Mavik is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mavik's family patents as well as insights into ongoing legal events on those patents.

Mavik's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Mavik's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 28, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Mavik Generics:

Trandolapril is the generic name for the brand Mavik. 10 different companies have already filed for the generic of Mavik, with Aurobindo Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Mavik's generic

How can I launch a generic of Mavik before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Mavik's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Mavik's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Mavik -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
1 mg, 2 mg and 4 mg 04 Oct, 2004 1 12 Jun, 2007 12 Jun, 2007 Extinguished

Alternative Brands for Mavik

Mavik which is used for treating congestive heart failure., has several other brand drugs using the same active ingredient (Trandolapril). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Abbvie
Tarka


Apart from brand drugs containing the same ingredient, some generics have also been filed for Trandolapril, Mavik's active ingredient. Check the complete list of approved generic manufacturers for Mavik





About Mavik

Mavik is a drug owned by Abbvie Inc. It is used for treating congestive heart failure. Mavik uses Trandolapril as an active ingredient. Mavik was launched by Abbvie in 1996.

Approval Date:

Mavik was approved by FDA for market use on 26 April, 1996.

Active Ingredient:

Mavik uses Trandolapril as the active ingredient. Check out other Drugs and Companies using Trandolapril ingredient

Treatment:

Mavik is used for treating congestive heart failure.

Dosage:

Mavik is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL